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Background: ASSURE-CSU revealed differences in physician and patient reporting
of angioedema. This post hoc analysis was conducted to evaluate the actual rate of
angioedema in the study population and explore differences between patients with
and without angioedema.
Methods: This international observational study assessed 673 patients with inade-
quately controlled chronic spontaneous urticaria (CSU). Physicians abstracted
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angioedema data from medical records, which were compared with patient-reported
data. Patients in the Yes-angioedema category had angioedema reported in the medi-
cal record and a patient-reported source. For those in the No-angioedema category,
angioedema was reported in neither the medical record nor a patient-reported
source. Those in the Misaligned category had angioedema reported in only one
source. Statistical comparisons between Yes-angioedema and No-angioedema cate-
gories were conducted for measures of CSU activity, health-related quality of life
(HRQoL), productivity and healthcare resource utilization (HCRU). Regression analy-
ses explored the relationship between Dermatology Life Quality Index (DLQI) score
and angioedema, adjusting for important covariates.
Results: Among evaluable patients, 259 (40.3%), 173 (26.9%) and 211 (32.8%) were
in the Yes-angioedema, No-angioedema and Misaligned category, respectively. CSU
activity and impact on HRQoL, productivity, and HCRU was greater for Yes-angioe-
dema patients than No-angioedema patients. After covariate adjustment, mean DLQI
score was significantly higher (indicating worse HRQoL) for patients with angioe-
dema versus no angioedema (9.88 vs 7.27, P < .001). The Misaligned category had
similar results with Yes-angioedema on all outcomes.
Conclusions: Angioedema in CSU seems to be under-reported but has significant
negative impacts on HRQoL, daily activities, HCRU and work compared with no
angioedema.
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1 | INTRODUCTION
Chronic spontaneous urticaria (CSU) is characterized by the presence
of hives, angioedema or both, recurring for 6 weeks or longer, in the
absence of identifiable triggers.1,2 Angioedema is defined as rapid
swelling at a deeper level under the skin than hives, occurring on
the face, inside the mouth or elsewhere on the body.2,3 It is esti-
mated that 33%-67% of patients with CSU exhibit both hives and
angioedema, 29%-65% exhibit only hives and 1%-13% exhibit only
angioedema.4,5
Patients who experience CSU as concurrent hives and angioe-
dema often experience a longer duration of disease than patients
who experience only hives.6,7 Angioedema may be disfiguring or
painful, may limit daily activities and may have a significant impact
on quality of life.8,9 Patients with CSU-associated angioedema often
experience concern over their health status, at times worrying that
swelling episodes may cause problems with breathing or may be life-
threatening.9 A real-world multicentre study in Germany has shown
that in a 6-month period, more than 40% of patients with inade-
quately controlled CSU experienced angioedema; among these
patients, 78% rated their angioedema as severe or moderate in
intensity, and a mean of 34 days with angioedema was reported dur-
ing the 6-month period.5 In addition to its considerable symptom
burden, recurrent angioedema (in those with hereditary angioedema)
can lead to absenteeism and can have a negative impact on work
productivity.10
The observational, multinational ASSURE-CSU (ASsessment of
the Economic and Humanistic Burden of Chronic Spontaneous/Idio-
pathic URticaria PatiEnts) study aimed to characterize the patient
population with inadequately controlled CSU and to evaluate the
burden of disease.11,12 Analyses of ASSURE-CSU data revealed
Highlights
 Nearly one-third of CSU patients in ASSURE-CSU
reported having experienced angioedema in the past
12 months but did not have physician-reported angioe-
dema as documented in their medical records.
 Patients with angioedema had greater CSU activity,
HRQoL and productivity impairment, and resource uti-
lization than those without. After controlling for other
factors, angioedema significantly affected DLQI total
score.
 Among patients with inadequately controlled symp-
tomatic CSU, the proportion with angioedema may be
higher than previously thought.
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different rates of CSU-associated angioedema between physician
and patient reports.12 The objectives of this post hoc analysis were
to provide a better estimate of angioedema rates among CSU
patients in the ASSURE-CSU study by aligning patient and physician
reports and to analyse differences in patient characteristics as well
as humanistic and economic burden between individuals with and
without angioedema.
2 | METHODS
2.1 | ASSURE-CSU study design
ASSURE-CSU was an observational, noninterventional, multinational,
multicentre study conducted at urticaria specialty centres in Canada,
France, Germany, Italy, Spain, the Netherlands and the United King-
dom. Methodology11 and overall results12 have been reported previ-
ously. In summary, recruitment of 700 patients was planned. Adult
patients who had a clinician-confirmed CSU diagnosis, had received at
least one treatment course with an H1-antihistamine, had been symp-
tomatic for more than 12 months and were currently symptomatic
despite treatment were eligible12; patients with urticaria that was pre-
dominantly of the inducible form were ineligible. Study data were col-
lected via a retrospective 12-month patient medical record abstraction
(MRA) by physicians, a cross-sectional patient survey and a prospective
8-day patient diary. The appropriate national-, local- and site-level ethi-
cal approvals were obtained, and all patients provided written informed
consent. The study complied with the Declaration of Helsinki.13
2.2 | Study measures
Study measures relevant to this analysis included the occurrence of
angioedema as reported in the physician MRA, the cross-sectional
patient survey and the patient diary. Specifically, physicians reported
from the medical chart whether the patient had angioedema associ-
ated with his or her CSU ever, at the time of diagnosis, and/or
within the past 12 months. In the patient survey, completed at
enrolment, patients answered whether they had experienced angioe-
dema ever, during the past 12 months, within the past 4 weeks and/
or currently (at survey completion); patients also answered questions
about the duration and location of angioedema, as well as the symp-
toms they experienced with angioedema (swelling, itching and pain)
and what they would do to seek treatment (or not) during an angioe-
dema episode. In the Urticaria Patient Daily Diary (UPDD), com-
pleted for each of 7 days following enrolment, patients indicated
whether they had experienced “rapid swelling, also called angioe-
dema,” during the past 24 hours.
Additional measures explored in this analysis included demo-
graphic data, comorbidities and healthcare resource utilization
(HCRU) related to CSU during the previous 12 months, as abstracted
by physicians in the MRA. Additional measures collected in the
patient survey included validated patient-reported outcome mea-
sures such as the Chronic Urticaria Quality of Life Questionnaire
(CU-Q2oL)
14,15 and Dermatology Life Quality Index (DLQI)16 and
HCRU. The 7-day UPDD17 also included the twice-daily Urticaria
Activity Score over 7 Days (UAS7TD),
18 daily sleep interference and
activity impairment, in addition to the aforementioned occurrence
and management of angioedema. On the 8th day, patients com-
pleted the Work Productivity and Activity Impairment (WPAI), which
has a recall period of 7 days.19
2.3 | Statistical analysis
Frequency of angioedema within the past 12 months and misalign-
ment of angioedema reporting between physician and patient data
sources were evaluated. For patients in the Yes-angioedema category,
physician and patient data sources agreed that the patient had expe-
rienced angioedema. For these cases, the MRA and either the patient
survey or patient diary indicated that the patient had experienced
angioedema in the past 12 months. For patients in the No-angioe-
dema category, physician and patient data sources agreed that the
patient had not experienced angioedema. For these cases, all 3 data
sources indicated no angioedema in the past 12 months. For the Mis-
aligned category, the physician and patient data sources (either
patient survey or diary) did not agree as to whether the patient had
experienced angioedema. For these cases, the physician data source
indicated no angioedema during the past 12 months while one of the
patient sources indicated that angioedema had occurred, or the
physician source indicated that the patient had experienced angioe-
dema in the past 12 months while the patient sources did not. If the
angioedema classification was missing either from the MRA or from
both patient data sources (survey and diary), the patient was assigned
to a Missing category and excluded from analysis.
Descriptive statistics were used to characterize the study popula-
tion by angioedema classification (Yes-angioedema, No-angioedema,
Misaligned). Disease activity was determined by UAS7TD score bands:
UAS7TD = 0-6 (urticaria-free or well-controlled urticaria activity), 7-
15 (mild activity), 16-27 (moderate activity) and 28-42 (severe activ-
ity).20 Health-related quality of life (HRQoL) measures were analysed
by published methodology where available.
Statistical comparisons of patients with and without angioedema
were conducted using t tests or Kruskal-Wallis tests for continuous
variables and chi-square tests for categorical variables. Tests were
performed between those in the Yes-angioedema and No-angioedema
categories; patients who fell into the Misaligned category were not
included in the statistical comparisons.
Regression modelling was used to explore whether the relation-
ship between DLQI score and angioedema remained significant after
adjusting for important covariates. An analysis of covariance model
was used to evaluate the effect of angioedema on DLQI total score.
Adjustment covariates included UAS7TD score, age, sex, country, dis-
ease duration from diagnosis to enrolment and selected comorbidi-
ties at enrolment (hypersensitivity to nonsteroidal anti-inflammatory
drugs, Hashimoto’s disease and asthma). UAS7TD score, age and dis-
ease duration were treated as continuous variables. Least-squares
mean estimates and standard errors were estimated for each angioe-
dema classification; patients in the Misaligned category were
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combined with patients in the Yes-angioedema category for the pri-
mary analysis. A sensitivity analysis was also conducted in which the
Misaligned category was excluded from the comparison.
All tests were performed at a nominal significance level of
a = .05 with 2-sided, single degree-of-freedom tests. No correction
was made for multiple comparisons. All analyses were performed
using SAS for Windows statistical software, version 9.4 (SAS Insti-
tute, Inc., Cary, NC, USA).
3 | RESULTS
3.1 | Initial angioedema frequency over the past
12 months
According to the MRA, physicians reported that 276 of 673 patients
enrolled (41.0%) had experienced CSU-associated angioedema within
the past 12 months, with a mean (standard deviation [SD]) of 19.0
(42.13) angioedema episodes during this period. Among the 649
patients who completed the survey, 427 (65.8%) patients reported
having had angioedema within the past 12 months (Figure 1A).
Among the 614 patients who completed the diary over 1 week,
294 (47.9%) patients reported that they had angioedema at least
1 day; the mean (SD) patient-reported number of days with angioe-
dema was 3.2 (1.92) over the 7 days. The occurrence of angioedema
and number of days with angioedema increased with increasing dis-
ease activity over that week.12
3.2 | Postalignment angioedema frequency over the
past 12 months
Of the 673 patients enrolled, 643 patients had recorded data for
assigning the angioedema classification, and 30 patients had missing
data either in the MRA or from both patient data sources (survey
and diary) and could not be classified. Of the 643 patients included
in the angioedema analyses, 276 (42.9%) had angioedema according
to the MRA, and 467 (72.6%) had angioedema according to one of
the patient sources (survey or diary).
For the analyses, 259 patients (40.3%) were in the Yes-angioe-
dema category, 173 (26.9%) were in the No-angioedema category,
and 211 (32.8%) were in the Misaligned category. Of the 211
patients in the Misaligned category, 205 (97.2%) had angioedema
recorded in one of the patient sources (survey or diary) but not in
the MRA (Figure 1B; Table S1).
3.3 | Patient demographics
There were no significant differences in baseline characteristics
between patients in the Yes-angioedema and No-angioedema cate-
gories, except in duration of CSU and presence of Hashimoto’s disease
(Table 1). Patients in the Yes-angioedema category had longer mean
(SD) duration of disease from diagnosis to enrolment (61.7 [76.64]
months) than those in the No-angioedema category (46.1 [69.06])
(P < .05) and a higher prevalence of Hashimoto’s disease (10.4% vs
2.9%; P < .01).
3.4 | Urticaria severity and activity
More patients in the Yes-angioedema category were reported to have
severe CSU activity at diagnosis (37.8%) than those in the No-angioe-
dema category (26.0%) (Table 1). Mean (SD) UAS7TD score reported in
the patient diary was higher for patients in the Yes-angioedema cate-
gory (17.6 [10.55]) than for those in the No-angioedema category (14.6
[8.97]) (P < .01) (Figure 2). In line with this observation, more patients
in the Yes-angioedema category than in the No-angioedema category
F IGURE 1 Frequency of angioedema in
the past 12 months. (A) Initial frequency:
Angioedema in the past 12 months was
more frequently reported by patients who
completed the survey (65.8%, 427/649
patients) than recorded in the medical
record (41.0%, 276/673 patients).
(B) Revised frequency: Of the 32.8% of
patients (211/643) with misaligned
reporting of angioedema in the past
12 months, 97.2% (205/211) reported
having had angioedema when it was not
noted in the medical record
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had severe (UAS7TD 28-42) disease activity (18.9% vs 12.4%) (Fig-
ure S1).19 Moreover, a significant difference was observed between
patients in the Yes-angioedema and No-angioedema categories in the
mean (SD) absolute number of hives over a week collected in the
UPDD (147.9 [266.37] vs 77.1 [123.87], respectively).
3.5 | Effect of angioedema on HRQoL, sleep and
daily activities
The mean (SD) CU-Q2oL score for the overall patient sample was
33.6 (21.02). Mean (SD) CU-Q2OL scores differed significantly
between patients in the Yes-angioedema and No-angioedema cate-
gories (37.6 [20.81] vs 23.4 [17.12], P < .001), reflecting significantly
lower HRQoL for patients with angioedema (Figure 3A). Significant
differences were observed between patients with and without
angioedema on all CU-Q2oL domains.
On the DLQI, mean (SD) overall score for the entire sample was
9.1 (6.63) and for Yes-angioedema and No-angioedema groups were
10.4 (6.85) and 6.6 (5.21), respectively (P < .001) (Figure 3B). Again,
significant differences were observed between patients with and
without angioedema on all DLQI domains (Figure 3C). More patients
in the Yes-angioedema category (45.5%) than in the No-angioedema













Age at enrolment (years) .0906
Mean (SD) 49.0 (15.56) 49.4 (14.45) 46.8 (16.50) 50.4 (15.95)
Min, Max 19.0, 89.0 20.0, 81.0 19.0, 89.0 19.0, 87.0
Female sex (%) 469 (72.9) 197 (76.1) 117 (67.6) 155 (73.5) .0540
Race and ethnicityc 544 205 155 184 .5262
Caucasian/White (%) 491 (90.3) 189 (92.2) 138 (89.0) 164 (89.1)
Other (%) 44 (8.1) 15 (7.3) 14 (9.0) 15 (8.2)
Data not available (%) 9 (1.7) 1 (0.5) 3 (1.9) 5 (2.7)
Disease duration from diagnosis to enrolment (months) .0486
Mean (SD) 57.3 (77.73) 61.7 (76.64) 46.1 (69.06) 61.0 (85.43)
Comorbid conditions at enrolment (%)
Hypersensitivity to NSAIDs 52 (8.1) 28 (10.8) 10 (5.8) 14 (6.6) .0833
Hashimoto’s disease 43 (6.7) 27 (10.4) 5 (2.9) 11 (5.2) .0042
Asthma 71 (11.0) 33 (12.7) 18 (10.4) 20 (9.5) .5434
CSU/CIU severity at the time of diagnosis (%) 642 259 173 210 .0101
Mild 71 (11.1) 27 (10.4) 32 (18.5) 12 (5.7)
Moderate 202 (31.5) 81 (31.3) 53 (30.6) 68 (32.4)
Severe 233 (36.3) 98 (37.8) 45 (26.0) 90 (42.9)
Data not available 136 (21.2) 53 (20.5) 43 (24.9) 40 (19.0)
UAS7TD
Mean (SD) UAS7TD 17.3 (10.46) 17.6 (10.55) 14.6 (8.97) 19.2 (11.05) .0032
UAS7TD band (%) 600 244 161 195 .0140
0-6 98 (16.3) 41 (16.8) 28 (17.4) 29 (14.9)
7-15 204 (34.0) 75 (30.7) 73 (45.3) 56 (28.7)
16-27 182 (30.3) 82 (33.6) 40 (24.8) 60 (30.8)
28-42 116 (19.3) 46 (18.9) 20 (12.4) 50 (25.6)
CIU, chronic idiopathic urticaria; CSU, chronic spontaneous urticaria; Q1, first quartile; Q3, third quartile; MRA, medical record abstraction; NSAIDs, non-
steroidal anti-inflammatory drugs; SD, standard deviation; UAS7TD, Urticaria Activity Score over 7 Days, twice-daily assessment.
aFor categorical variables, the total number of patients with nonmissing data is presented by angioedema category for each question along with “n (%)”
for each possible response to the question. Except where otherwise noted, percentage denominators are the number of patients with nonmissing data
for the applicable question.
bP values shown from t tests for means of continuous variables and chi-square tests for frequencies of categorical variables to compare patients who
experience angioedema (Yes-angioedema) with those who do not (No-angioedema). Patients in the Misaligned category were not included in the statistical
comparison. For race and ethnicity, due to the small number of patients in many of the race/ethnicity categories, all races other than white were com-
bined for these comparisons. Patients whose race/ethnicity group is “data not available” were excluded from the statistical comparison.
cRace and ethnicity data were not collected in France. For some categories of race and ethnicity, different terms were used across countries.
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category (20.4%) had DLQI scores >10 (indicating a very to extre-
mely large effect on HRQoL21).
As patients reported on the UPDD, mean (SD) weekly scores for
interference with sleep were higher for patients in the Yes-angioe-
dema category (6.9 [6.14]) than for patients in the No-angioedema
category (4.6 [4.92]) (P < .001), as were mean (SD) weekly scores for
interference with daily activities (6.5 [5.68] vs 4.8 [4.39]; P < .05)
(Figure 3D). Activity impairment measured by the mean percentage
overall activity impairment score on the WPAI was also greater for
patients in the Yes-angioedema category than for patients in the No-
angioedema category (34.5% vs 23.8%; P < .001) (Figure 4).
3.6 | Economic and societal impact of angioedema
Patients in the Yes-angioedema category had greater HCRU, both
documented in medical records and self-reported, than patients in
the No-angioedema category (Table S2). According to the MRA,
patients in the Yes-angioedema category were more likely to have a
CSU-related emergency department visit than patients in the No-
angioedema category (24.7% vs 5.2%, P < .001) and were more likely
to have one or more inpatient hospital stays in the past 12 months
(11.6% vs 3.5%, P < .01). As reported in the patient diary, patients
with angioedema were more likely to call a healthcare provider dur-
ing the 7-day window than patients without angioedema (7.3% vs
0.6%, P < .01).
Impact on work was greater among patients in the Yes-angioe-
dema category than among patients in the No-angioedema category.
Patients in the Yes-angioedema category who completed the diary
were more likely to have missed 1 or more hours of work in the 7-
day diary window than patients in the No-angioedema category
(27.6% vs 5.8%, P < .001), and mean (SD) number of days of work
missed in the past 3 months was significantly higher for patients in
the Yes-angioedema versus the No-angioedema category (4.7 [11.64])
vs 0.8 [3.86], P < .001). WPAI scores showed significantly greater
absenteeism among patients in the Yes-angioedema versus No-angioe-
dema categories (mean [SD] percentage absenteeism: 9.1% [23.22%]
vs 1.4% [9.08%], P < .001), as well as significantly greater overall
work impairment (mean [SD] percentage overall work impairment:
29.2% [28.48%) vs 19.1% [21.37%], P = .02) (Figure 4). Overall,
angioedema was the second most common reason for missing work,
after itching.
3.7 | Characteristics of the misaligned angioedema
category
Patients in the Misaligned category were compared descriptively with
patients in the Yes-angioedema and No-angioedema categories and
were found to be most similar to patients in the Yes-angioedema cat-
egory in all outcomes. Demographics were similar in terms of age,
sex, disease duration from diagnosis to enrolment and CSU severity
at diagnosis (Table 1). Similar proportions of patients in the Misa-
ligned and Yes-angioedema categories had moderate (UAS7TD 16-27)
or severe (UAS7TD 28-42) disease activity (56.4% and 52.5%, respec-
tively). When completing the survey, 52.2% of patients in the Misa-
ligned category reported that their angioedema typically lasts more
than 12 hours, compared with 47.8% of patients in the Yes-angioe-
dema category. The mean (SD) amount of swelling, on a scale of 0
to 10, was similar for patients in the Misaligned category (7.1 [2.12])
and those in the Yes-angioedema category (7.2 [2.20]). In addition,
the HRQoL impact of CSU was similar for patients in the Misaligned
and Yes-angioedema categories, as indicated by mean (SD) overall
scores on the DLQI (10.4 [6.85] and 9.7 [6.87], respectively) and
CU-Q2oL (37.6 [20.81] and 37.0 [21.49], respectively) (Figure 3A,B).
Percentage overall work impairment due to CSU was similar for
patients in the Misaligned and Yes-angioedema categories (mean
[SD] = 31.5% [29.99%] and 29.2% (28.48%), respectively) (Figure 4).
3.8 | DLQI regression analysis
Given the similarities in characteristics and outcomes among patients
in the Misaligned and Yes-angioedema categories, the Misaligned
patients were combined with the Yes-angioedema patients in the pri-
mary regression analysis of DLQI total score. After covariate adjust-
ment, mean DLQI score was significantly higher for patients with
angioedema versus without (9.88 vs 7.27, P < .001) (Table 2).
Results were similar in the sensitivity analysis in which patients in
the Misaligned angioedema category were excluded: mean DLQI total
score was significantly higher for patients with angioedema versus
without (9.69 vs 6.73, P < .001).
F IGURE 2 Mean urticaria activity score over 7 days, twice-daily
assessment (UAS7TD), by angioedema classification. UAS7TD scores
were calculated by summing the average of twice-daily assessments
of hive count and itch score and summing these daily scores over
7 days. *P < .01 (Yes—angioedema vs No—angioedema). Patients who
fell into the Misaligned group were not included in the statistical
comparisons. SD, standard deviation. [Colour figure can be viewed at
wileyonlinelibrary.com]
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4 | DISCUSSION
The results of this post hoc analysis revealed notable differences in
reporting of angioedema between CSU patients and physicians in
the ASSURE-CSU study. The objective of this analysis was to align
angioedema data in order to better estimate the actual rate of
angioedema and to analyse differences between patients with and
without angioedema. Angioedema was more frequently reported by
patients than by physicians: 65.8% of patients who completed the
survey reported having experienced angioedema during the past
12 months, whereas physicians reported that 41.0% of patients had
experienced angioedema during the same time period. A large major-
ity (97%) of patients with misaligned angioedema data did not have
physician-reported angioedema but reported having experienced
angioedema in either the patient survey or diary. These findings sug-
gest that the occurrence of angioedema may be under-recognized
among physicians (who may not routinely ask patients about angioe-
dema symptoms), that patients may not always report their angioe-
dema symptoms to physicians or that patients characterize some
CSU-related swelling as angioedema when a physician would classify
it as hives or sometimes as swelling unrelated to urticaria.
ASSURE-CSU patients with misaligned angioedema data appear
most similar to patients with angioedema, in terms of disease duration;
disease activity; and scores on patient-reported outcome measures
including the CU-Q2oL, DLQI and WPAI. If patients in the Misaligned
category were reclassified into the Yes-angioedema category, which
they closely resembled, the percentage of patients in the ASSURE-CSU
study with angioedema over 12 months would increase from 40.3% to
73.1%. Moreover, our analysis suggests that patients with more severe
CSU are more likely to have angioedema. Physicians reported that more
patients with angioedema than without had severe CSU at diagnosis,
and patients with angioedema reported greater CSU activity as indi-
cated by UAS7TD mean score than those without angioedema.
The primary ASSURE-CSU analysis found that angioedema had a
significant impact on HRQoL in patients with CSU, particularly with
respect to emotional well-being, fatigue and mood.12 The current
analysis also revealed the considerable impact of angioedema on
HRQoL, as indicated by CU-Q2oL and DLQI scores, and its additional
negative impact on top of itch and hives. Even after controlling for
other factors, angioedema has a significant effect on the DLQI total
score. In addition, patients with angioedema have additional impair-
ment on work productivity and more HCRU than those without it,
indicating that angioedema further contributes to the economic bur-
den of inadequately controlled CSU.
Taken together, findings from these analyses suggest that
physicians should ensure that patients understand the manifesta-
tions of angioedema and should routinely assess patients with
CSU for presence of angioedema, which may enable more accu-
rate estimates of the true prevalence and burden of angioedema.
Appropriate tools available for evaluating angioedema activity and
its impact on CSU patients’ lives should be used regularly in clini-
cal practice.22-24 In patients with recurrent angioedema, CSU
should be considered as one of the differential diagnoses.1,25
Additionally, angioedema in CSU should prompt adequate treat-
ment. The development of new treatments specifically for CSU
has been shown to prevent angioedema and improve angioedema-
dependent and dermatology-related quality of life.9,26-28 Future
research should explore the clinical course of angioedema in CSU
—including the most commonly affected areas, the clinical differ-
ences compared with hereditary angioedema and evolution of
symptoms over time—as well as the distinct management patterns
that patients with angioedema in CSU require. Understanding the
underlying mechanisms of angioedema in CSU29 and exploring dif-
ferences in the general categories of angioedema (ie mast cell–in-
duced and bradykinin-induced) are also important areas for
additional research.
Several limitations must be considered when the results of this
study are interpreted. First, the study was conducted in specialized
centres only, and physicians and centres were not selected systemat-
ically, owing to the small number of specialist units for this popula-
tion. The resulting sample is not guaranteed to be representative of
all medical settings and physicians treating patients with CSU. Sec-
ond, the target population had had CSU for at least 12 months and
had not responded adequately to treatment at the time of inclusion
in the study; thus, the study does not reflect the entire population
of patients with CSU but more patients with inadequately controlled
CSU. Moreover, although patients received training about identifying
angioedema and reporting it in the patient survey or diary, like all
patient-reported data, angioedema was still subject to patients’ indi-
vidual interpretation of the symptom description and manifestation.
In addition, data extracted by physicians from medical records were
not independently validated.
5 | CONCLUSIONS
Among this study population with inadequately controlled CSU,
40.3% had confirmed angioedema in the past 12 months, and 32.8%
F IGURE 3 Impact of CSU on HRQoL, sleep and daily activities, overall and by angioedema classification. (A) CU-Q2oL total and domain
scores. Different CU-Q2oL scale scores are used in Germany than in Canada, France, Italy, the Netherlands, Spain and the UK. German CU-
Q2oL overall score and scale scores are presented in Figure S2; (B) DLQI total score; (C) DLQI domain scores; (D) Interference with sleep and
interference with daily activities over a week, as reported on the Urticaria Patient Daily Diary, by angioedema classification. For all scores, a
higher score means higher impairment. *P < .001 (Yes—angioedema vs No—angioedema); **P < .05 (Yes—angioedema vs No—angioedema).
Patients who fell into the misaligned category were not included in the statistical comparisons. CU-Q2oL, Chronic Urticaria Quality of Life
Questionnaire; DLQI, Dermatology Life Quality Index; HRQoL, health-related quality of life; SD, standard deviation. [Colour figure can be
viewed at wileyonlinelibrary.com]
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of patients had misaligned angioedema data (ie the majority reporting
having experienced angioedema in the past 12 months without hav-
ing it documented in their medical records). This suggests that a
higher proportion of patients with inadequately controlled symp-
tomatic CSU might have angioedema than previously thought.
Patients with angioedema reported statistically significantly worse
HRQoL and higher societal burden than patients without angioe-
dema; patients in the Misaligned group reported similar impairment
as patients with confirmed angioedema. Overall, the study found that
angioedema has an incremental impact on societal and humanistic
outcomes in CSU patients. These findings suggest the need for
improved physician-patient communication regarding angioedema for
better symptom control in patients with inadequately controlled CSU.
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F IGURE 4 Work productivity and activity impairment (WPAI) results by angioedema classification. Absenteeism was defined as percentage
of work time missed due to chronic spontaneous urticaria (CSU) in the past 7 days. Presenteeism was defined as percentage impairment while
working due to CSU in the past 7 days. Overall work impairment was defined as percentage work impairment due to CSU in the past 7 days,
incorporating both absenteeism and presenteeism using the following validated WPAI algorithm: overall work impairment = absenteeism + (1-
absenteeism)*presenteeism. *P < .001 (Yes—angioedema vs No—angioedema); **P < .05 (Yes—angioedema vs No—angioedema). Patients who fell
into the misaligned category were not included in the statistical comparisons. SD, standard deviation; WPAI, Work Productivity and Activity
Impairment. [Colour figure can be viewed at wileyonlinelibrary.com]
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